Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

MLA

Naidoo, Jarushka, et al. “Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 35, no. 7, Mar. 2017, pp. 709–17. EBSCOhost, https://doi.org/10.1200/JCO.2016.68.2005.

APA

Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., Rosenberg, J., Voss, M. H., Rudin, C. M., Rizvi, H., Hou, X., Rodriguez, K., Albano, M., Gordon, R.-A., Leduc, C., … Hellmann, M. D. (2017). Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35(7), 709–717. https://doi.org/10.1200/JCO.2016.68.2005

Chicago

Naidoo, Jarushka, Xuan Wang, Kaitlin M Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E Chaft, et al. 2017. “Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35 (7): 709–17. doi:10.1200/JCO.2016.68.2005.